CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

Rhea-AI Summary

CytoMed Therapeutics (NASDAQ: GDTC) on December 8, 2025 announced a Memorandum of Understanding with Universiti Malaya Medical Centre to establish a multi-site, first-in-human Phase I clinical trial in Malaysia to test its donor-derived unmodified gamma delta (γδ) T cells (CTM-GDT) for patients with limited treatment options. This program complements CytoMed’s ongoing Phase I CAR T trial in Singapore using engineered γδ T cells (CTM-N2D). CytoMed is co-author of a September 2025 research article reporting promising preclinical/early results for donor-derived Vγ9Vδ2 T cells in acute myeloid leukemia, supporting further clinical study.

The collaboration aims to evaluate safety and efficacy of allogeneic off-the-shelf γδ T cells and to expand access to affordable immunotherapy in Southeast Asia.

Positive

• Memorandum of Understanding signed with UMMC on Dec 8, 2025
• First-in-human Phase I trial planned in Malaysia to test CTM-GDT
• Co-author on a September 2025 publication supporting CTM-GDT potential

Negative

• Trial is Phase I; no established clinical efficacy yet
• Announcement is an MOU; trial execution and outcomes are not guaranteed

Key Figures

LongevityBank investment US$500,000 Non-dilutive commitment from ICH Capital for 10.0% post-money stake

Post-money stake 10.0% Ownership in LongevityBank granted to ICH Capital

Proposed share sale 54,644 shares Shares registered for sale in Form 144 filed 2025-09-22

Shares outstanding 11,733,712 shares Total outstanding reported in Form 144

Offering shares 2,432,172 shares Shares assumed issued in 424B5 prospectus supplement

Chairman ownership 21.95% Effective holding including related entities as of 2025-10-22

ANGELICA milestone Dose Level 1 completed First-in-human Phase I CTM-N2D trial in advanced cancers

Malaysia trial phase Phase I First-in-human CTM-GDT trial for no-option cancer patients in Malaysia

Market Reality Check

$1.77 Last Close

Volume Volume 11,532 is about 0.18x the 20-day average of 62,955, indicating subdued trading before this news. low

Technical Shares at $1.77 were trading below the $2.18 200-day MA and about 56.3% under the 52-week high.

Peers on Argus

Biotech peers showed mixed moves: FBLG up 4.64%, while LIXT, NRXS and QTTB declined between about 2–9%. With GDTC down 0.55% pre-news and no peers in momentum scanners, trading appeared stock-specific rather than a coordinated sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 06	Subsidiary investment	Positive	-3.3%	Non-dilutive US$500,000 investment into LongevityBank and China strategy update.
Oct 22	Insider purchase	Positive	+4.3%	Executive Chairman increased effective holdings to 21.95% through open-market buys.
Oct 14	Asset acquisition bid	Positive	+16.6%	Cash bid for TC BioPharm T-cell assets to deepen gamma delta T-cell expertise.
Oct 02	Preclinical data	Positive	+0.0%	Publication with MD Anderson showing potential of allogeneic γδ T cells in AML.
Aug 28	Acquisition update	Positive	-0.5%	Post-acquisition update on Malaysian cord blood bank and dual-strategy structure.

Pattern Detected

Recent news often skews positive in tone, but price reactions have been mixed, with slightly more divergence than alignment and sizeable upside mainly on asset-acquisition headlines.

Recent Company History

Over the last six months, CytoMed reported several strategic milestones. On Aug 28, 2025, it detailed expansion into auto-immune diseases via a Malaysian cord blood bank acquisition. A Oct 14, 2025 cash bid for TC BioPharm assets boosted gamma delta T-cell capabilities and saw a 16.58% move. Subsequent updates on MD Anderson AML research and a US$500,000 non-dilutive LongevityBank investment reinforced focus on allogeneic cell therapies, setting the stage for today’s Malaysia Phase I collaboration.

Market Pulse Summary

This announcement expands CytoMed’s clinical footprint with a first-in-human Phase I trial of donor-derived γδ T cells in Malaysia, complementing its ongoing ANGELICA study in Singapore and a planned Phase 2 trial in India. Investors may track enrollment progress, safety signals, and future readouts, alongside previously disclosed financing tools such as the Form 144 and 424B5 offering, to gauge how clinical advances align with capital needs.

Key Terms

allogeneic medical

"CytoMed’s patented allogeneic unmodified Gamma Delta (γδ) T cells"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

autologous medical

"Most immunotherapies today are autologous, meaning the cells are manufactured"

Autologous describes a medical product or treatment made from a patient’s own cells or tissues rather than from a donor. For investors, autologous approaches matter because they can lower the risk of immune rejection and improve effectiveness, but they often require individualized manufacturing, complex logistics, and higher per-patient costs—factors that affect scalability, pricing, and regulatory hurdles in healthcare businesses.

car t medical

"Phase I chimeric antigen receptor (“CAR”) T clinical trial at National"

CAR T is a type of immunotherapy that reprograms a patient’s own white blood cells to recognize and attack cancer cells, like giving immune cells a custom GPS to find and destroy tumors. It matters to investors because CAR T therapies can offer durable responses for hard-to-treat cancers, but they also involve complex manufacturing, high costs, regulatory hurdles and market access challenges that affect a company’s revenue potential and risk profile.

immunotherapy medical

"an affordable cancer immunotherapy option to patients with limited treatment"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

acute myeloid leukemia medical

"Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising"

A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.

AI-generated analysis. Not financial advice.

SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”) a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma Delta (γδ) T cells (“CTM-GDT”) (without genetically modifying the cells to express any receptor) for no-option cancer patients in Malaysia.

This initiative complements CytoMed’s ongoing first-in-human Phase I chimeric antigen receptor (“CAR”) T clinical trial at National University Hospital Singapore, which uses γδ T cells engineered to express a proprietary CAR (“CTM-N2D”) designed to target a wide range of cancers, including advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinoma.

CytoMed’s Chairman, Peter Choo, commented: “This collaboration with UMMC will pave the way for an affordable cancer immunotherapy option to patients with limited treatment alternatives and is based on the human body’s natural T cells innate ability to detect and kill cancer cells. Most immunotherapies today are autologous, meaning the cells are manufactured from the patient’s own blood. CytoMed’s technology, however, is allogeneic, meaning we manufacture a rare and specialized subset of T cells called γδ T cells from healthy donors, which is produced at high purity and do not trigger immune rejection in patients. Compared to autologous therapy, allogeneic technology is significantly more cost-effective to manufacture, offers lower, speedier and simpler logistics, making it more accessible to patients, including those from overseas.”

Unmodified γδ T cells have been demonstrated in international clinical trials to possess the potential to kill cancer cells. CytoMed is co-author of a September 2025 publication in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach”. The study results arising from CytoMed’s collaborative research with The University of Texas, MD Anderson Cancer Center (“MDACC”), suggest great potential of CytoMed’s CTM-GDT for treating acute myeloid leukemia . This collaboration with MDACC is conducted under a research agreement announced in May 2023. The research article is publicly and freely accessible online.

“These exciting and encouraging findings support the rationale for further clinical study of allogeneic γδ T cells in cancer treatments. It will facilitate our endeavor to advance our unmodified γδ T cells into the clinical setting in Southeast Asia and bring novel immunotherapy options to patients with limited treatment alternatives.” added Peter Choo.

“At UMMC, our priority is to expand access to promising and scientifically robust treatment options for Malaysian patients. We are pleased to collaborate with CytoMed on this pioneering first-in-human trial, which explores the potential of donor-derived γδ T cells as an accessible immunotherapy approach for cancers with limited therapeutic options. This partnership reflects our shared commitment to advancing clinical innovation for the benefit of our community.” said Professor Dr. Lim Soo Kun, Head of Clinical Investigation Centre of UMMC.

About CytoMed Therapeutics Limited (CytoMed)

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.

Forward Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

Contact:

CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention : Evelyn Tan, Chief Corporate Officer

FAQ

What did CytoMed (GDTC) announce on December 8, 2025 regarding clinical trials in Malaysia?

CytoMed announced an MOU with UMMC to establish a multi-site first-in-human Phase I trial testing donor-derived unmodified γδ T cells (CTM-GDT).

How does the Malaysia CTM-GDT trial relate to CytoMed's other trials (GDTC)?

The Malaysia CTM-GDT Phase I trial complements an ongoing Phase I CAR T trial in Singapore using engineered γδ T cells (CTM-N2D).

What is the goal of the Phase I CTM-GDT trial announced by CytoMed (GDTC)?

The trial will investigate the safety and efficacy of allogeneic donor-derived unmodified γδ T cells in no-option cancer patients.

What evidence supports CytoMed's CTM-GDT program as of December 2025 (GDTC)?

CytoMed is co-author of a September 2025 research article reporting encouraging results for donor-derived Vγ9Vδ2 T cells in acute myeloid leukemia.

Will CytoMed's Malaysia trial use genetically modified cells (GDTC)?

No; the Malaysia trial will test unmodified donor-derived γδ T cells (CTM-GDT), not gene-modified or CAR-expressing cells.